Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

Loss or mutation of TP53 has been linked to alterations in anti-tumor immunity as well as dysregulation of cell cycle and apoptosis. We explored immunologic effects and mechanisms following restoration of wild-type human TP53 cDNA in murine oral cancer cells using the therapeutic nanocomplex scL-53....

Full description

Bibliographic Details
Main Authors: Ellen C. Moore, Lillian Sun, Paul E. Clavijo, Jay Friedman, Joe B. Harford, Anthony D. Saleh, Carter Van Waes, Esther H. Chang, Clint T. Allen
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:OncoImmunology
Subjects:
adaptive immune resistance
checkpoint inhibitor
gene therapy
immunity
nanocomplex
sting
tp53
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1404216

Internet

http://dx.doi.org/10.1080/2162402X.2017.1404216

Similar Items